What is the limitation on third-party participation in patent term extension proceedings?

According to MPEP 2763, third-party participation in patent term extension proceedings is significantly limited. The section states: “No submission on behalf of third parties, in the form of protests or otherwise, will be considered by the Office. Any such submissions by third parties to the Office will be returned to the party making the submission,…

Read More

How is a Certificate of Extension of Patent Term issued?

The process of issuing a Certificate of Extension of Patent Term involves several steps: The Director determines the patent’s eligibility for extension based on the application. If eligible and requirements are met, a certificate is issued under seal. The certificate is recorded in the official patent file. Notification of issuance is published in the Official…

Read More

What happens if a third party submits information regarding a patent term extension proceeding?

According to MPEP 2763, any submissions made by third parties regarding patent term extension proceedings will not be considered by the USPTO. The section clearly states: “Submissions by third parties not requested by the Office will be returned, or otherwise disposed of, without consideration.“ This policy is enforced to maintain the ex parte nature of…

Read More

What happens if the USPTO receives a FOIA request for confidential information in a patent term extension application?

If the United States Patent and Trademark Office (USPTO) receives a Freedom of Information Act (FOIA) request for confidential information in a patent term extension application, specific procedures are followed. According to MPEP 2760: “Should the Office receive a Freedom of Information Act (FOIA) request for the material, the applicant will be provided notice and…

Read More

How does the “first permitted marketing or use” requirement affect patent term extension eligibility?

The “first permitted marketing or use” requirement is a crucial factor in determining eligibility for patent term extension. According to 35 U.S.C. 156(a)(5) and 37 CFR 1.720(e), the approval for commercial marketing or use must generally be the first permitted under the provision of law under which the regulatory review occurred. For human drug products:…

Read More